Science Explorer Back to mapMap
Discussion
Company · Bothell · United States

OncoGenex Pharmaceuticals (United States)

oncogenex.comROR OpenAlex
World rank, all time
#32,844
of 34,923
Rank in United States
#6,893
of 7,310
Research works
142
▲ 536% vs 2018-21
Citations
11k
77.0 per fractional work
Top-10% rate
3.8%
all institutions 10.0%
vs its own fields
1.25×
1.00× is exactly expected
Open access
33%
world 40%
International
12%
world 18%
OncoGenex Pharmaceuticals (United States)

Which fields of science does OncoGenex Pharmaceuticals (United States) work in?

In all years, 58% of research at OncoGenex Pharmaceuticals (United States) is in Life Sciences, 32% in Health Sciences. Its largest fields are Biochemistry, Genetics and Molecular Biology (38%), Medicine (31%), Immunology and Microbiology (16%). It does 3.5× the world's share of Life Sciences.

Life Sciences: 82 fractional works · 57.7% of its workBiochemistry, Genetics and Molecular Biology: 53 fractional works · 37.6% of its workMolecular Biology: 36 fractional works · 25.4% of its workGenetics: 8 fractional works · 6.0% of its workCell Biology: 3 fractional works · 2.0% of its workBiotechnology: 3 fractional works · 1.9% of its workCancer Research: 2 fractional works · 1.2% of its workBiophysics: 0 fractional works · 0.4% of its workBiochemistry: 0 fractional works · 0.2% of its workClinical Biochemistry: 0 fractional works · 0.2% of its workEndocrinology: 0 fractional works · 0.2% of its workImmunology and Microbiology: 23 fractional works · 16.4% of its workImmunology: 20 fractional works · 14.0% of its workVirology: 3 fractional works · 2.1% of its workMicrobiology: 0 fractional works · 0.2% of its workNeuroscience: 2 fractional works · 1.6% of its workCellular and Molecular Neuroscience: 2 fractional works · 1.4% of its workNeurology: 0 fractional works · 0.2% of its workAgricultural and Biological Sciences: 2 fractional works · 1.4% of its workAnimal Science and Zoology: 1 fractional works · 0.5% of its workAgronomy and Crop Science: 1 fractional works · 0.4% of its workGeneral Agricultural and Biological Sciences: 0 fractional works · 0.4% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPharmacology, Toxicology and Pharmaceutics: 1 fractional works · 0.8% of its workPharmacology: 1 fractional works · 0.5% of its workPharmaceutical Science: 0 fractional works · 0.3% of its workHealth Sciences: 45 fractional works · 31.6% of its workMedicine: 44 fractional works · 31.0% of its workRadiology, Nuclear Medicine and Imaging: 13 fractional works · 9.1% of its workOncology: 13 fractional works · 8.9% of its workEndocrinology, Diabetes and Metabolism: 3 fractional works · 2.3% of its workEpidemiology: 2 fractional works · 1.5% of its workImmunology and Allergy: 2 fractional works · 1.4% of its workPathology and Forensic Medicine: 2 fractional works · 1.2% of its workPulmonary and Respiratory Medicine: 1 fractional works · 0.9% of its workGenetics: 1 fractional works · 0.8% of its workPhysiology: 1 fractional works · 0.8% of its workSurgery: 1 fractional works · 0.7% of its workPublic Health, Environmental and Occupational Health: 1 fractional works · 0.6% of its workInfectious Diseases: 1 fractional works · 0.4% of its workNeurology: 1 fractional works · 0.4% of its workHepatology: 1 fractional works · 0.4% of its workPharmacology: 0 fractional works · 0.4% of its workSmaller subfields together: 2 fractional works · 1.2% of its workHealth Professions: 1 fractional works · 0.5% of its workMedical Laboratory Technology: 1 fractional works · 0.5% of its workDentistry: 0 fractional works · 0.1% of its workPhysical Sciences: 10 fractional works · 7.3% of its workEngineering: 6 fractional works · 4.5% of its workBiomedical Engineering: 6 fractional works · 3.9% of its workMedia Technology: 0 fractional works · 0.4% of its workElectrical and Electronic Engineering: 0 fractional works · 0.2% of its workChemistry: 1 fractional works · 1.0% of its workOrganic Chemistry: 1 fractional works · 0.8% of its workSpectroscopy: 0 fractional works · 0.2% of its workComputer Science: 1 fractional works · 0.7% of its workInformation Systems: 1 fractional works · 0.5% of its workComputer Networks and Communications: 0 fractional works · 0.2% of its workSmaller subfields together: 0 fractional works · 0.0% of its workEnvironmental Science: 1 fractional works · 0.6% of its workEcology: 1 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.1% of its workPhysics and Astronomy: 0 fractional works · 0.4% of its workStatistical and Nonlinear Physics: 0 fractional works · 0.4% of its workMaterials Science: 0 fractional works · 0.2% of its workSocial Sciences: 5 fractional works · 3.3% of its workDecision Sciences: 2 fractional works · 1.4% of its workInformation Systems and Management: 2 fractional works · 1.4% of its workSocial Sciences: 1 fractional works · 1.0% of its workEducation: 1 fractional works · 0.7% of its workSmaller subfields together: 0 fractional works · 0.3% of its workBusiness, Management and Accounting: 1 fractional works · 0.8% of its workStrategy and Management: 1 fractional works · 0.5% of its workSmaller subfields together: 0 fractional works · 0.2% of its workEconomics, Econometrics and Finance: 0 fractional works · 0.1% of its workALL ITS WORKOncoGenexPharmaceuticals…142fractional works, all years
Life Sciences58%Physical Sciences7%Health Sciences32%Social Sciences3%

Each ring splits the one inside it: the four domains of science, their fields, their subfields. Size is fractional works in all years. Every slice is a page; the interactive view zooms down to single topics and colours each by how much more of it this institution does than the world.

Its 4 domains and 18 fields, with their numbers
    1. Biochemistry, Genetics and Molecular Biology5337.6%
    2. Immunology and Microbiology2316.4%
    3. Neuroscience21.6%
    4. Agricultural and Biological Sciences21.4%
    5. Pharmacology, Toxicology and Pharmaceutics10.8%
    1. Medicine4431.0%
    2. Health Professions10.5%
    3. Dentistry00.1%
    1. Engineering64.5%
    2. Chemistry11.0%
    3. Computer Science10.7%
    4. Environmental Science10.6%
    5. Physics and Astronomy00.4%
    6. Materials Science00.2%
    1. Decision Sciences21.4%
    2. Social Sciences11.0%
    3. Business, Management and Accounting10.8%
    4. Economics, Econometrics and Finance00.1%
All of science, and how each field's share has moved since 1950: the Science domain explorer

Field profile

Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.

Agricultural and Biological Sciences: 0.61× its world share, 0 worksAgricultural and Bio…Biochemistry, Genetics and Molecular Biology: 5.38× its world share, 2 worksBiochemistry, Geneti…Neuroscience: 0.89× its world share, 0 worksNeuroscienceEngineering: 1.35× its world share, 1 worksEngineeringDentistry: 2.97× its world share, 0 worksDentistryMedicine: 1.16× its world share, 1 worksMedicineBusiness, Management and Accounting: 4.48× its world share, 1 worksBusiness, Management…Economics, Econometrics and Finance: 1.35× its world share, 0 worksEconomics, Econometr…Social Sciences: 0.46× its world share, 0 worksSocial Sciences1×world share
more than its size predictsabout as predictedless

Rings at 0.5×, 1× and 2×. Widest outward: Biochemistry, Genetics and Molecular Biology, 5.4×. Every wedge is a field page.

All 9 fields, with their numbers
  1. Biochemistry, Genetics and Molecular Biology5.38×2 works
  2. Business, Management and Accounting4.48×1 works
  3. Dentistry2.97×0 works
  4. Engineering1.35×1 works
  5. Economics, Econometrics and Finance1.35×0 works
  6. Medicine1.16×1 works
  7. Neuroscience0.89×0 works
  8. Agricultural and Biological Sciences0.61×0 works
  9. Social Sciences0.46×0 works

Who are the top researchers at OncoGenex Pharmaceuticals (United States)?

Ranked on the quality score, Daniel R. Twardzik, A F Purchio and Cindy A. Jacobs lead among researchers whose main affiliation is OncoGenex Pharmaceuticals (United States).

  1. 1 Daniel R. Twardzik United States · #202,036 worldwide 8.4k citations · 85 works
  2. 2 A F Purchio United States · #275,813 worldwide 9.6k citations · 91 works
  3. 3 Cindy A. Jacobs United States · #564,025 worldwide 2.4k citations · 77 works
  4. 4 Mario N. Lioubin United States · #592,135 worldwide 3.6k citations · 31 works
  5. 5 A F Purchio United States · #2,459,438 worldwide 1.5k citations · 23 works
All ranked researchers at OncoGenex Pharmaceuticals (United States)

What are the most cited papers from OncoGenex Pharmaceuticals (United States)?

The most cited paper from OncoGenex Pharmaceuticals (United States) is "T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1." (Peter S. Linsley, Edward A. Clark, Jeffrey A. Ledbetter, 1990), with 755 citations. Next come "Role of the CD28 receptor in T-cell activation" (681) and "Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family" (600).

Most cited papers
#PaperReleasedCitations
1 T-cell antigen CD28 mediates adhesion with B cells by interacting with activation antigen B7/BB-1. Peter S. Linsley, Edward A. Clark, Jeffrey A. Ledbetter · Proceedings of the National Academy of Sciences Open access Jul 1990 755
2 Role of the CD28 receptor in T-cell activation Carl H. June, Jeffrey A. Ledbetter, Peter S. Linsley et al. · Immunology Today 1990 681
3 Structure and Function of Human Amphiregulin: A Member of the Epidermal Growth Factor Family MOHAMMED SHOYAB, Gregory D. Plowman, Vicki L. McDonald et al. · Science 24 Feb 1989 600
4 Production of transforming growth factor beta 1 during repair of arterial injury. Mark W. Majesky, Volkhard Lindner, Daniel R. Twardzik et al. · Journal of Clinical Investigation Open access Sep 1991 533
5 T-Cell Proliferation Involving the CD28 Pathway Is Associated witH Cyclosporine-Resistant Interleukin 2 Gene Expression Carl H. June, Jeffrey A. Ledbetter, Marjorie Gillespie et al. · Molecular and Cellular Biology Open access Dec 1987 529
All 59 most cited papers, with filters and sorting

Which keywords describe research at OncoGenex Pharmaceuticals (United States)?

By fractional works in all years, weighted toward what it does more of than the world: Glycosylation, Cancer, Monoclonal Antibodies, Therapeutic Antibodies, Antibody Engineering, Fc Receptors, Angiogenesis and Immune Response.

▲ more of its work than of the world's◆ about the world's share▼ less than the world's

Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 40 words are chosen for being large and distinctive. Each links to the topic it comes from most.

All 40 words, with their numbers
  1. Glycosylation23▲ 74×3 topics
  2. Cancer21▲ 11×19 topics
  3. Monoclonal Antibodies12▲ 61×2 topics
  4. Therapeutic Antibodies12▲ 68×2 topics
  5. Antibody Engineering12▲ 83×1 topic
  6. Fc Receptors12▲ 83×1 topic
  7. Angiogenesis11▲ 18×11 topics
  8. Immune Response10▲ 11×7 topics
  9. Inflammation8▲ 2.6×17 topics
  10. Cancer Therapy8▲ 8.8×9 topics
  11. Monoclonal Antibody8▲ 77×2 topics
  12. Innate Immunity7▲ 14×8 topics
  13. Autoimmunity7▲ 23×4 topics
  14. Gene Therapy7▲ 18×4 topics
  15. Biopharmaceutical Production7▲ 60×2 topics
  16. Cancer Immunotherapy6▲ 33×3 topics
  17. Cell Culture6▲ 41×2 topics
  18. Glycans6▲ 56×1 topic
  19. Immune System6▲ 14×1 topic
  20. Genomic Integration6▲ 39×2 topics
  21. Immunotherapy6▲ 6.0×9 topics
  22. Antigen Presentation5▲ 38×2 topics
  23. Cancer Progression5▲ 17×4 topics
  24. Foxp35▲ 51×1 topic
  25. TGF-ß5▲ 22×1 topic
  26. Tumor Microenvironment5▲ 11×5 topics
  27. Mammalian Cells5▲ 92×1 topic
  28. Recombinant Protein5▲ 92×1 topic
  29. Immunity5▲ 10×4 topics
  30. Transcriptional Regulation5▲ 14×5 topics
  31. Dendritic Cells4▲ 27×1 topic
  32. Extracellular Matrix4▲ 13×4 topics
  33. Tumor Antigen4▲ 38×1 topic
  34. Vaccine4▲ 7.8×5 topics
  35. AAV4▲ 46×1 topic
  36. Viral Vectors4▲ 46×1 topic
  37. Breast Cancer4▲ 9.8×4 topics
  38. Metastasis4▲ 8.1×5 topics
  39. Tumor Suppression4▲ 24×3 topics
  40. PET Imaging4▲ 11×4 topics

Which research topics does OncoGenex Pharmaceuticals (United States) publish most on?

By volume in 2022-now: 3D Printing in Biomedical Research, Smoking Behavior and Cessation, Global Trade and Competitiveness and Metabolism, Diabetes, and Cancer.

3D Printing in Biomedica…13D Printing in Biomedical Research: 1 fractional worksSmoking Behavior and Ces…0Smoking Behavior and Cessation: 0 fractional worksGlobal Trade and Competi…0Global Trade and Competitiveness: 0 fractional worksMetabolism, Diabetes, and Cancer: 0 fractional worksCancer, Hypoxia, and Metabolism: 0 fractional worksCancer-related Molecular Pathways: 0 fractional worksNicotinic Acetylcholine Receptors Study: 0 fractional worksAdvanced Fluorescence Microscopy Techniques: 0 fractional worksAgriculture Market Analysis Ukraine: 0 fractional worksFinancial Literacy, Pension, Retirement Analysis: 0 fractional works
Biomedical EngineeringPhysiologyStrategy and ManagementMolecular Biology5 others

Area is fractional works; colour is the subfield each topic belongs to.

  1. 1 3D Printing in Biomedical Research Biomedical Engineering 1 works
  2. 2 Smoking Behavior and Cessation Physiology 0 works
  3. 3 Global Trade and Competitiveness Strategy and Management 0 works
  4. 4 Metabolism, Diabetes, and Cancer Molecular Biology 0 works
  5. 5 Cancer, Hypoxia, and Metabolism Cancer Research 0 works
  6. 6 Cancer-related Molecular Pathways Oncology 0 works
  7. 7 Nicotinic Acetylcholine Receptors Study Molecular Biology 0 works
  8. 8 Advanced Fluorescence Microscopy Techniques Biophysics 0 works
  9. 9 Agriculture Market Analysis Ukraine General Agricultural and Biological Sciences 0 works
  10. 10 Financial Literacy, Pension, Retirement Analysis Accounting 0 works

How open and international is its research?

Against the world's own shares: the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.

openly available33.0%not open67.0%

World: 40% of research is openly available.

with international co-authors12.5%domestic only87.5%

World: 18% is written across borders.

How has OncoGenex Pharmaceuticals (United States)'s research output changed?

Output in 2022-2025 was 536% higher than in 2018-2021.

still counting1990200020102020
grewheldshrank

The same series as a ribbon: one cell per year, darker for more. The line above answers how much; this answers when.

Its share of all research

Growing output can still be a shrinking share: all of science grows. This is OncoGenex Pharmaceuticals (United States) as a percentage of every work published that year, 0.000027% in 2024.

still counting0.0020%0.0040%OncoGenex Pharmaceuticals (United States)0.000020% in 20251990200020102020

Fractional works of OncoGenex Pharmaceuticals (United States) over all fractional works that year. How the balance of science has shifted.

Other research institutions in Bothell

All research institutions in Bothell

Share OncoGenex Pharmaceuticals (United States)'s ranking

OncoGenex Pharmaceuticals (United States) on Science Explorer

A card with OncoGenex Pharmaceuticals (United States)'s standing and the fields it leads in, for a post or a slide. A link to this page previews as the same card.

Download the card

1200 × 630 PNG, sized for social posts, drawn from the latest snapshot.

Badges for a website1Each links back here and updates with every snapshot

Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners have tabs of their own, above.

Discussion

Ask a question or share a note about OncoGenex Pharmaceuticals (United States). Keep it to the research: no personal attacks, advertising or links. Any reader can report a post, which collapses it for everyone until it is opened.